Ixo-vec
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07630649 | Jun 2026 → Jun 2031 expected | wet macular degeneration | Adverum Biotechnologies, Inc. | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07482176 | Mar 2026 → Nov 2027 expected | wet macular degeneration | Adverum Biotechnologies, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06856577 | Feb 2025 → Dec 2026 expected | wet macular degeneration | Adverum Biotechnologies, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ixo-vec | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07630649 ↗ |
| Known as | AAV.7m8-aflibercept | “Ixo-vec (also known as Ixoberogene soroparvovec, ADVM-022 or AAV.7m8-aflibercept) is an adeno-associated virus (AAV)-based gene therapy designed to enable sustained intraocular...” NCT07630649 ↗2“Ixo-vec (also known as ADVM-022 or AAV.7m8-aflibercept) is an adeno-associated virus (AAV)-based gene therapy product being developed for the treatment of nAMD.” NCT07482176 ↗ “Ixo-vec (also known as ADVM-022 or AAV.7m8-aflibercept)” NCT06856577 ↗ |
| Known as | ADVM-022 | “Ixo-vec (also known as Ixoberogene soroparvovec, ADVM-022 or AAV.7m8-aflibercept) is an adeno-associated virus (AAV)-based gene therapy designed to enable sustained intraocular...” NCT07630649 ↗2“Ixo-vec (also known as ADVM-022 or AAV.7m8-aflibercept) is an adeno-associated virus (AAV)-based gene therapy product being developed for the treatment of nAMD.” NCT07482176 ↗ “Ixo-vec (also known as ADVM-022 or AAV.7m8-aflibercept)” NCT06856577 ↗ |
| Known as | Ixoberogene Soroparvovec | “Ixo-vec (also known as Ixoberogene soroparvovec, ADVM-022 or AAV.7m8-aflibercept) is an adeno-associated virus (AAV)-based gene therapy designed to enable sustained intraocular...” NCT07630649 ↗2“Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)” NCT07482176 ↗ “Ixoberogene Soroparvovec (Ixo-vec)” NCT06856577 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “Ixo-vec (also known as ADVM-022 or AAV.7m8-aflibercept) is an adeno-associated virus (AAV)-based gene therapy product being developed for the treatment of nAMD.” NCT07482176 ↗ |
| Route | Intravitreal | “Ixo-vec will be administered intravitreally.” NCT06856577 ↗ |